Abstract
Parkinsons disease is a neurodegenerative movement disorder caused by a combination of environmental and genetic factors. Recent human genetic studies have identified five genes that are linked to Parkinsons disease (PD): α-synuclein, parkin, UCH-L1, DJ-1 and NR4A2. Among these genes, a variety of mutations in the human parkin locus have been found in many PD cases, both familial and sporadic. Parkin appears to be the most prevalent genetic factor in PD. It encodes for a protein-ubiquitin E3 ligase, whose loss-offunction mutations cause specific degeneration of dopamine (DA) neurons in substantia nigra in human patients. The accumulation of parkin substrates is thought to be the key factor in the selective death of DA neurons. Rapid progress in the identification of these substrates and the generation of genetic animal models has produced a plethora of knowledge about the biological function of parkin and its role in PD. These studies also offer novel pharmacological targets for the development of more selective therapeutic strategies. In this review, I will summarize results from this fast expanding field and discuss their potential implication in the treatment of Parkinsons disease.
Keywords: parkin, synuclein, parkinson's disease, ubiquitination, misfolding, microtubule, dopamine, tubulin
Current Neuropharmacology
Title: Genetic Factors in Parkinsons Disease and Potential Therapeutic Targets
Volume: 1 Issue: 4
Author(s): Jian Feng
Affiliation:
Keywords: parkin, synuclein, parkinson's disease, ubiquitination, misfolding, microtubule, dopamine, tubulin
Abstract: Parkinsons disease is a neurodegenerative movement disorder caused by a combination of environmental and genetic factors. Recent human genetic studies have identified five genes that are linked to Parkinsons disease (PD): α-synuclein, parkin, UCH-L1, DJ-1 and NR4A2. Among these genes, a variety of mutations in the human parkin locus have been found in many PD cases, both familial and sporadic. Parkin appears to be the most prevalent genetic factor in PD. It encodes for a protein-ubiquitin E3 ligase, whose loss-offunction mutations cause specific degeneration of dopamine (DA) neurons in substantia nigra in human patients. The accumulation of parkin substrates is thought to be the key factor in the selective death of DA neurons. Rapid progress in the identification of these substrates and the generation of genetic animal models has produced a plethora of knowledge about the biological function of parkin and its role in PD. These studies also offer novel pharmacological targets for the development of more selective therapeutic strategies. In this review, I will summarize results from this fast expanding field and discuss their potential implication in the treatment of Parkinsons disease.
Export Options
About this article
Cite this article as:
Feng Jian, Genetic Factors in Parkinsons Disease and Potential Therapeutic Targets, Current Neuropharmacology 2003; 1 (4) . https://dx.doi.org/10.2174/1570159033477053
| DOI https://dx.doi.org/10.2174/1570159033477053 |
Print ISSN 1570-159X |
| Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |
Call for Papers in Thematic Issues
Advances and Integrative Approaches to Gut-Brain Interactions
Disorders of gut-brain interaction (DGBIs), formerly known as functional gastrointestinal disorders, involve dysfunction of complex signaling pathways between the gastrointestinal tract and the central nervous system. These disorders span the esophagus (functional heartburn, functional dysphagia), stomach (functional dyspepsia), and intestines (irritable bowel syndrome, chronic constipation), and are increasingly recognized as ...read more
Advances in Neuroimaging: Bridging Pharmacology, Nanotechnology, and Neurological Disorders
This special topic seeks to compile cutting-edge research and reviews that explore the synergy between neuroimaging, pharmacology, and nanotechnology in understanding and treating neurological disorders. We aim to elucidate novel imaging biomarkers for tracking drug efficacy and disease progression in conditions such as Alzheimer’s, Parkinson’s, multiple sclerosis, and brain tumors. ...read more
Advances in Neuroinflammation and Neuroprotection: Mechanisms and Therapeutic Frontiers
It offers a comprehensive exploration of neuroinflammatory and neuroprotective pathways that play central roles in a range of neurological disorders, including stroke, traumatic brain injury, and neurodegenerative diseases such as Alzheimer’s and Parkinson’s. This issue invites research on the cellular and molecular mechanisms driving neuroinflammation, such as the roles of ...read more
Advances in Neurovascular Unit in Stroke and Neurodegenerative Disease: Mechanisms and Therapeutic Frontiers
The main goal of this special issue is to analyze current knowledge of the functional roles of various types of cells in neurovascular units(NVU) in neurodegenerative diseases such as stroke, Alzheimer's disease, and Parkinson's disease. This issue invites research on the cellular and molecular mechanisms driving inflammation, blood-brain barrier(BBB) injury, ...read more
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Strategies for Skeletal Muscle Targeting in Drug Discovery
Current Pharmaceutical Design Mechanisms of Metallic Nanomaterials to Induce an Antibacterial Effect
Current Topics in Medicinal Chemistry Central Serotonin2C Receptor: From Physiology to Pathology
Current Topics in Medicinal Chemistry Analgesic Drug Use Associated with Statin Prescription – A Cross- Sectional Study in Primary Care Settings
Current Drug Safety Current Concepts of Pain Pathways: A Brief Review of Anatomy, Physiology, and Medical Imaging
Current Medical Imaging New Uses of Melatonin as a Drug; A Review
Current Medicinal Chemistry Development and Evaluation of a Tactile Cognitive Function Test Device for Alzheimer’s Disease Early Detection
Neuroscience and Biomedical Engineering (Discontinued) Cognitive Dysfunction in Major Depressive Disorder: A State-of-the-Art Clinical Review
CNS & Neurological Disorders - Drug Targets Recent Approaches and Success of Liposome-Based Nano Drug Carriers for the Treatment of Brain Tumor
Current Drug Delivery Glutamate Receptors in Human Caudate Nucleus in Normal Aging and Alzheimer’s Disease
Current Alzheimer Research Clinical Trials with Intracerebral Convection-Enhanced Delivery of Targeted Toxins in Malignant Glioma
Reviews on Recent Clinical Trials Structure-Based Drug Design, Molecular Dynamics and ADME/Tox to Investigate Protein Kinase Anti-Cancer Agents
Current Bioactive Compounds Topical and Transdermal Drug Delivery: From Simple Potions to Smart Technologies
Current Drug Delivery Pathologically-Activated Therapeutics for Neuroprotection: Mechanism of NMDA Receptor Block by Memantine and S-Nitrosylation
Current Drug Targets Current Status and Recent Developments in Anthracenone Antipsoriatics
Current Pharmaceutical Design The Association of Hot/Cold Status of Temperament with Depression and Hopelessness Scores in Females
Current Traditional Medicine Stereotyped Paroxysmal Psychiatric Symptoms During Oculogyric Crisis or ‘Cognitive Dystonia’: A Case Report
Current Drug Safety The Effects of Locus Coeruleus and Norepinephrine in Methamphetamine Toxicity
Current Neuropharmacology Cognitive Behavioral Therapy for Psychosis Prevention and Treatment in Youth
Current Psychiatry Reviews Therapeutic Nucleic Acids
Recent Patents on Regenerative Medicine





